Bruker Co. (NASDAQ:BRKR) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. decreased its position in Bruker Co. (NASDAQ:BRKR) by 6.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 219,884 shares of the medical research company’s stock after selling 15,857 shares during the quarter. JPMorgan Chase & Co. owned 0.15% of Bruker worth $15,185,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. True Wealth Design LLC increased its position in shares of Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after purchasing an additional 510 shares during the last quarter. UMB Bank n.a. grew its stake in shares of Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after purchasing an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Bruker in the 2nd quarter worth approximately $52,000. GAMMA Investing LLC boosted its stake in Bruker by 81.0% during the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after buying an additional 388 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in Bruker during the third quarter valued at approximately $73,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Wall Street Analyst Weigh In

BRKR has been the subject of several research analyst reports. UBS Group began coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target for the company. Citigroup decreased their price target on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. TD Cowen cut their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target on the stock in a research note on Thursday, December 5th. Finally, Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Bruker currently has an average rating of “Moderate Buy” and an average price target of $74.45.

Bruker Stock Performance

BRKR stock opened at $60.78 on Friday. The stock has a market capitalization of $9.21 billion, a PE ratio of 29.22, a price-to-earnings-growth ratio of 4.00 and a beta of 1.17. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The company has a 50 day moving average price of $57.77 and a 200 day moving average price of $61.85. Bruker Co. has a fifty-two week low of $48.07 and a fifty-two week high of $94.86.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. During the same quarter in the prior year, the business earned $0.74 EPS. Bruker’s revenue was up 16.4% on a year-over-year basis. Analysts forecast that Bruker Co. will post 2.4 EPS for the current year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.33%. Bruker’s payout ratio is presently 9.62%.

Insider Buying and Selling at Bruker

In related news, CEO Frank H. Laukien purchased 100,000 shares of the stock in a transaction dated Monday, November 18th. The stock was bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the purchase, the chief executive officer now directly owns 38,439,563 shares in the company, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 28.30% of the company’s stock.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.